At Rueb Stoller Daniel, we are committed to fighting for the rights of those who have been harmed by negligence and unsafe products. With extensive experience in mass tort cases, we focus on providing personalized
At Rueb Stoller Daniel, we are a dedicated team of legal professionals committed to helping clients navigate complex legal challenges. With years of experience, we focus on fighting for those who have suffered due to
At Rueb Stoller Daniel, we fight for individuals harmed by PFAS exposure and other dangerous chemicals. Our team has extensive experience in mass tort litigation, holding corporations accountable for toxic contamination and its serious health
At Rueb Stoller Daniel, we are dedicated to fighting for individuals harmed by dangerous products, including talcum powder lawsuits against major manufacturers like Johnson & Johnson. Our experienced mass tort lawyers have helped thousands of
At Rueb Stoller Daniel, we have over 50 years of combined experience fighting for individuals harmed by dangerous products and corporate negligence. Our attorneys have successfully handled mass tort cases, wrongful death claims, and catastrophic
Paraquat is a highly toxic herbicide that has been widely used in agricultural settings for decades. While it is an effective weed killer, growing concerns about its severe health risks have led to numerous lawsuits
At Rueb Stoller Daniel, we are a national law firm dedicated to fighting for justice through mass tort and class action litigation. Our experienced attorneys, including Gregory Rueb, Paul Stoller, and Stephen Daniel, have represented
Settling a claim for a class action lawsuit involves a detailed process to ensure that the settlement funds are fairly and accurately distributed among the affected parties. From attorney fees and administrative costs to payouts
Filing a Roundup lawsuit can be a big deal for people who believe their health has been affected by the popular weed killer, especially the active ingredient glyphosate which has been linked to non-Hodgkin’s lymphoma.
Oxbryta, a medication developed to treat anemia in individuals with Sickle Cell Disease (SCD), initially offered hope for improving the lives of those managing this challenging condition. However, as its use became widespread, alarming side
Oxbryta, a medication initially designed to treat anemia in individuals with Sickle Cell Disease (SCD), was once hailed as a breakthrough in improving hemoglobin levels and reducing the effects of sickled red blood cells. However,
Oxbryta, once seen as a promising treatment for Sickle Cell Disease (SCD), aimed to improve hemoglobin levels and reduce the complications of sickle-shaped red blood cells, including acute pain crises. However, its recall in 2024
